Small Cap Feast
Small Cap Feast – 24th February 2017
Dish of the Day:
Saffron Energy –Expected to join AIM today. Has Hydrocarbon producing assets in Italy
Saffron Energy –Expected to join AIM today. Has Hydrocarbon producing assets in Italy
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
GBGI—Schedule One update from integrated provider of international benefits insurance. Raising £32m at 150p. Admission expected tomorrow.
Anglo African Oil & Gas— Admission expected early March. Acquiring stake in producing near offshore field in the Republic of the Congo.
Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Issue closing 23 Feb.
PowerHouse Energy Group (PHE.L) 1p £8.94m
PowerHouse has agreed with University of Chester to deploy its G3-UHt unit (ultra-high temperature demonstration gasification system) at its Thornton Science Park, adjacent to the newly constructed Energy Centre of the University – a facility providing flexible space where industry and academia come together to innovate, develop, and demonstrate new, intelligent, energy technologies. The Company has entered into a heads of terms with the University to take offices at Thornton Science Park to support the G3 Unit and to allow potential customer and partner evaluation of the G3 system.
IDOX (IDOX.L) 72.25p £292m
AGM Statement from the supplier of information management software solutions and services to the public sector. “Idox has made a strong start to the new financial year building on the good performance and organic and acquisitive growth of 2016, with trading for the current financial year in line with our expectations. We are seeing a solid pipeline of opportunities and are pleased to have recently secured significant contracts in healthcare and transport and continuing wins across other segments.” Recently launched IDOX Health has won contracts with two acute hospital trusts and has been awarded a grant by NHS England to develop a product to improve hospital efficiency and improve treatment outcomes for in-patients in acute stroke care. FYOCT17E £94.7m rev and £22.1m PBT.
Sound Energy (SOU.L) 89.25p £600m
The African and European focused upstream gas company, announced that the third Tendrara well, TE-8, has now been drilled to the first casing point at a measured depth (“MD”) of 461 metres and that the 13 3/8″ casing is being set and cemented in the top of Upper Lias formation. The Company will now proceed to drill towards the second casing point at an MD of approximately 2,070 metres.
Cloudtag (CTAG.L) 22.25p £21.85m
The Company that brings personal monitoring to the wellbeing, fitness and digital health markets hereby announced that it has raised gross proceeds of £975,000 at 3.75p. The Subscription was completed with the clients of Novum Securities Limited. The Net Proceeds will be used for general working capital purposes. The Company is pre-revenue generating and is therefore dependent on its ability to raise further capital to continue its operations in the short term. The board is carefully managing the Company’s cash position. Cairn Financial Advisers has served notice on the Company that it will resign as the Company’s nominated advisers with effect from 10 April 2017. The company is in discussions with another NOMAD and broker.
Advanced Oncotherapy (AVO.L) 57.5p £41.68m
The developer of next generation proton therapy systems for cancer treatment, announced that further to the financing agreement with Bracknor announced on 22 February 2017, the first tranche has been drawn down by the Company and the initial funds of £1.3 million received (less 5%). Bracknor is prohibited from short selling ahead of any conversion notice, being the notice given to the Company that Bracknor wishes to convert the loan notes into AVO shares. Following the earlier grant of planning consent for the Harley St site a principal contactor has been appointed with excavation due to commence by the end of Q1.
Diversified Gas & Oil (DGOC.L) 62p £65.47m
The US based gas and oil producer, has reached a definitive agreement to acquire a package of producing gas and oil wells in the states of Ohio and Pennsylvania for $1.75m in cash. Expands held by production acreage by approximately 75,250 acres. Gas – 3,800 gross Mcfd, representing a 14% increase to current gross production. Oil – 110 gross bopd, representing a 23% increase to current gross production. Accretive to operating cash flow.
Atlantis Resources (ARL.L) 50.5p £59m
The specialist in the tidal power sector, confirms, following Monday’s announcement of the deployment of the first AR1500 tidal stream turbine at the MeyGen project site in the Pentland Firth, Scotland, that the 1.5 megawatt turbine has already successfully exported power to the grid and has operated at full power. The Atlantis AR1500 tidal stream turbine was successfully deployed in less than 60 minutes following earlier connection of its proprietary wet mate connection management system, which allows for rapid deployment and retrieval of the tidal stream turbine.
EU Supply (EUSP.L) 13.5p £9.14m
The e-procurement software provider, announced that it has been awarded a grant from the European Union for the development of additional features to its CTM™ platform. The Grant is expected to be worth up to €120,000 and to be received during 2017. It has been awarded for the development of certain additional features to the Company’s CTM™ platform in order to meet new legislative requirements in the EU/EEC countries. FYDEC16E rev of £3.4m and £1m pre-tax loss.
Edenville Energy (EDL.L) 0.85p £7.2m
As the Company is now concentrating on advancing activities at its Rukwa coal deposit, the Company’s exploration prospecting licence for uranium has been relinquished. This Matiri South licence (PL6147/2009) covers 28.5 sq km and was originally acquired for shares at the time of the Company’s admission to AIM in 2010. After initial investigation the licence area appears to contain little indication of economic mineralisation and no further work has subsequently been undertaken in connection with this licence. Cost savings of c.$32k but will incur an impairment charge.
Cambridge Cognition (COG.L) 77.5p £15.8m
Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition Kit Limited, a joint venture between Cambridge Cognition and Ctrl Group Limited, announced a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD). 30 participant study with output expected in H1.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.